SCHEMBL309328

SCHEMBL309328

COc1cc(OS(=O)(=O)C(F)(F)F)cc(C(C)(C)C)c1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.38
CA1 P00915 4/20 0.36
CA2 P00918 4/20 0.36
CA9 Q16790 2/20 0.36
HSD11B1 P28845 2/20 0.36
AKR1C3 P42330 2/20 0.35
AKR1C2 P52895 2/20 0.35
CYP1A1 P04798 1/20 0.35
CYP1B1 Q16678 1/20 0.35
RXRA P19793 1/20 0.35
RXRB P28702 1/20 0.35
RXRG P48443 1/20 0.35
MAPT P10636 2/20 0.33
TP53 P04637 1/20 0.33
THRB P10828 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
CXCR2 P25025 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1723540 0.89 CA1 (0.40) CA1CA2CA9HSD11B1RXRA
SCHEMBL1713657 0.89 ALDH1A1 (0.48) ALDH1A1CA1CA2CA9HSD11B1
SCHEMBL9958667 0.82 ALDH1A1 (0.44) ALDH1A1CA1CA2CA9HSD11B1
SCHEMBL3386175 0.82 ALDH1A1 (0.41) ALDH1A1AKR1C3AKR1C2CYP1A1CYP1B1
SCHEMBL509273 0.82 ALDH1A1 (0.41) ALDH1A1CA1CA2HSD11B1CYP1A1
SCHEMBL7367391 0.81 ADORA2A (0.44) ALDH1A1CYP1A1CYP1B1TP53
SCHEMBL926505 0.79 CA2 (0.41) CA1CA2CA9HSD11B1CXCR2
SCHEMBL278798 0.79 ALDH1A1 (0.61) ALDH1A1CA1CA2CA9CYP1A1
SCHEMBL23602225 0.78 CA1 (0.39) ALDH1A1CA1CA2CA9HSD11B1
SCHEMBL4730537 0.78 CYP1A1 (0.47) ALDH1A1CYP1A1CYP1B1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8093406-B2 Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors NOVARTIS AG (CH) 2012-01-10 US disclosed
EP-2303857-A1 CYCLIC SULFONES WITH AMINOBENZYL SUBSTITUTION USEFUL AS BACE INHIBITORS Novartis AG (CH) 2011-04-06 EP disclosed
US-20100056490-A1 Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors NOVARTIS AG (CH) 2010-03-04 US disclosed
WO-2010003976-A1 CYCLIC SULFONES WITH AMINOBENZYL SUBSTITUTION USEFUL AS BACE INHIBITORS NOVARTIS AG (CH) 2010-01-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056490-A1 Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors BACE2, BACE1, APP ALDH1A1 2566/4885CA1 169/4885CA2 101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.